Makindo Medical Notes"One small step for man, one large step for Makindo" |
![]() |
---|---|
Download all this content in the Apps now Android App and Apple iPhone/Pad App | |
MEDICAL DISCLAIMER: The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis, or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd. |
Related Subjects: |Urothelial tumour s |Haematuria |Acute Urinary Retention |Anuria and Oliguria |Bladder cancer |Renal cell carcinoma |Benign Prostatic Hyperplasia |IgA nephropathy |Prostate Cancer |Henoch-Schonlein purpura |Glomerulonephritis
π‘ RCC arises from renal tubule epithelium. Clear cell RCC = most common, VHL gene mutation, accounts for majority of deaths.
58-year-old smoker with intermittent painless haematuria and dull right flank pain; renal US shows a solid cortical lesion and contrast CT (renal protocol) confirms a 5.2 cm enhancing upper pole mass without nodes or vein thrombus; labs reveal mild anaemia and βALP; MDT plans nephron-sparing surgery with partial nephrectomy (T1b, favourable anatomy) to preserve renal function; no pre-op biopsy given classic imaging; pathology later shows clear cell RCC with negative marginsβpost-op plan: risk-adapted CT chest/abdomen surveillance, eGFR monitoring, and smoking cessation.
72-year-old with weight loss, bone pain, and hypercalcaemia; staging CT demonstrates an 8 cm left renal mass with renal vein/IVC thrombus and pulmonary nodules; MRI maps thrombus extent; per MDT, tissue diagnosis obtained because systemic therapy precedes surgery; commence immunotherapy/VEGF-TKI combination per IMDC risk, treat hypercalcaemia (IV fluids + bisphosphonate/denosumab), and consider cytoreductive nephrectomy only if good performance status and response to systemic therapy; palliative radiotherapy for painful bone metastases as needed.